ARQ vs INVE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARQ exhibits severe financial distress signals, with a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company reports negative profitability across key metrics—ROE of -27.31%, ROA of -1.97%, and a staggering -43.72% profit margin—despite modest revenue growth of 8.8% YoY. The absence of an Altman Z-Score and the lack of positive cash flow or earnings consistency further heighten insolvency concerns. Although insider sentiment is neutral and analysts rate it 'strong_buy', this is contradicted by a 60.7% one-year price decline and persistent earnings misses, suggesting a disconnect between market expectations and fundamentals.
Identiv, Inc. (INVE) exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all financial health dimensions. While the company maintains an exceptionally strong liquidity position (Current Ratio of 15.19) and negligible debt, these are offset by a disastrous profit margin of -83.80% and declining year-over-year revenue growth of -7.90%. The stock trades below book value (P/B 0.62), but this appears to be a value trap given the lack of earnings and negative technical trend. Despite recent earnings beats, the company remains consistently unprofitable with a bearish long-term price trajectory.
Compare Another Pair
Related Comparisons
ARQ vs INVE: Head-to-Head Comparison
This page compares Arq, Inc. (ARQ) and Identiv, Inc. (INVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.